This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

6 Stocks With Upgrades

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Macerich

The real estate investment trust last week reported fourth-quarter nt income of $162.1 million, or $1.23 a share, which increased from year-earlier earnings of $23.6 million, or 18 cents.

"External growth outlook also appears healthy, with three meaningful projects in the near-term (30 mos) pipeline. Fashion Outlets of Chicago is a $200M outlet development held in a 60/40 JV with AWE/Talisman (MAC share $120M)," Keefe, Bruyette & Woods analysts wrote in a report on Monday. "Comments last quarter pointed to a groundbreaking in Nov '11; recent comments suggest construction loan will be in place within next 30-45 days. Despite the delay, new outlet center is expected to open in Aug '13 and garner 10% to 11% yield. MAC also intends to expand Fashion Outlets of Niagara Falls; adding 200-250k sf to existing 530k sf center, which was purchased for $200M in July '11. Construction is expected to begin soon, with opening 2 years after. Finally, MAC continues to work towards densifying Tysons Corner Center; est $200M share investment to add 550k sf of office & 500k sf of retail to its existing 2.0M sf mall. Expansion is expected to open in '14."

Macerich was upgraded to a buy from a hold by TheStreet Ratings.

Of the 19 analysts who cover the company, 11 rated it a buy. The other eight analysts considered Macerich a hold.

Macerich's forward P/E is 55.2. The average for retail REITs is 52.64. Simon Property Group (SPG) and Realty Income (O) both have lower forward P/Es of 36.57 and 36.28, respectively.

TheStreet Ratings gives Macerich a B grade and $63.66 price target. The stock closed Monday at $55.20 and has increased 9.09% year to date.






Hologic

The surgical products company reported on Jan. 30 first-quarter earnings of $20.8 million, or 8 cents a share, an increase from year-ago fourth quarter earnings of $10.9 million, or 4 cents.

"We are reiterating our OUTPERFORM rating and $24 price target following HOLX's Q1/12 earnings release," Barrington Research analysts wrote in a Feb. 1 report. "We believe the women's health market is an attractive market opportunity. Given that HOLX is the clear leader of this market, investors should be appropriately aligned with this positive trend given the current valuation of HOLX's shares."

Hologic was upgraded to a buy from a hold by TheStreet Ratings.

Of the 24 analysts who cover the company, 15 rated it a buy. Eight considerd Hologic a hold and one rated it a sell.

Hologic has a forward P/E of 13.8. The average among medical supplies companies is 20.92. C.R. Bard (BCR) and Alere (ALR) both have lower forward P/Es of 13.29 and 9.55, respectively.

TheStreet Ratings gives Hologic a B- grade and $24.37 price target. The stock closed Monday at $20.79 and has risen 18.73% year to date.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,083.80 -2.83 -0.02%
S&P 500 1,987.98 +0.97 0.05%
NASDAQ 4,472.1080 -1.5890 -0.04%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs